Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma.

"Conflicts of interest The authors have no relevant disclosures."

"Funding information The study did not receive any external support, it was funded internally by the Hematology division at the Tel Aviv Sourasky Medical Center."

"This prospective cohort study investigated the efficacy of BNT162b2 mRNA COVID19 vaccine in patients diagnosed with MM, in a real‐world setting. The primary end‐point of the study was the seropositivity rate achieved following vaccination with BNT162b2 mRNA COVID19 vaccine, assessed by measuring the anti‐SARS‐CoV‐2S antibody titer pre and post vaccination. The study was approved by the institutional review board and is registered in ClinicalTrials.gov, number NCT04746092. All participants signed an informed consent form prior to their inclusion in the study."